Rosiglitazone attenuates the severity of hyperlipidemic severe acute pancreatitis in rats | Zendy

Niyaz Batur | Zendy; Kailiang Zhao | Zendy; Limin Liu | Zendy; Chen Chen | Zendy; Wenhong Deng | Zendy; Teng Zuo | Zendy; Qiao Shi | Zendy; Weixing Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rosiglitazone attenuates the severity of hyperlipidemic severe acute pancreatitis in rats

Author(s) -

Niyaz Batur,

Kailiang Zhao,

Limin Liu,

Chen Chen,

Wenhong Deng,

Teng Zuo,

Qiao Shi,

Weixing Wang

Publication year - 2013

Publication title -

experimental and therapeutic medicine

Language(s) - English

Resource type - Journals

eISSN - 1792-1015

pISSN - 1792-0981

DOI - 10.3892/etm.2013.1255

Subject(s) - rosiglitazone , hyperlipidemia , clofibrate , medicine , acute pancreatitis , endocrinology , peroxisome proliferator activated receptor , pancreatitis , molecular medicine , peroxisome , receptor , insulin resistance , pharmacology , chemistry , diabetes mellitus , insulin , cancer , cell cycle

Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand regulates adipocyte differentiation and insulin sensitivity, and exerts antihyperlipidemic and anti-inflammatory effects. However, the mechanisms by which PPAR-γ ligands affect hyperlipidemia with severe acute pancreatitis (SAP) have not been fully elucidated. The present study investigated the effects of rosiglitazone, a PPAR-γ ligand, on hyperlipidemia with SAP in a rat model. The hyperlipidemia was induced with a high-fat diet and SAP was induced by the administration of sodium taurocholate (TCA). The hyperlipidemia was shown to aggravate the severity of the sodium taurocholate-induced SAP. However, rosiglitazone demonstrated significant antihyperlipidemic and anti-inflammatory effects in the rats with high-lipid diet-induced hyperlipidemia and SAP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research